416 related articles for article (PubMed ID: 32342279)
1. Efficacy of Collagenase Clostridium histolyticum (Xiapex
Cocci A; Di Maida F; Russo GI; Capogrosso P; Francesco L; Rizzo M; Di Mauro M; Salonia A; Cito G; Falcone M; Romano A; Polloni G; Martinez-Salamanca JI; Fernández-Pascual E; Minervini A; Mondaini N
Clin Drug Investig; 2020 Jun; 40(6):583-588. PubMed ID: 32342279
[TBL] [Abstract][Full Text] [Related]
2. Predictive Factors of Patients' and Their Partners' Sexual Function Improvement After Collagenase Clostridium Histolyticum Injection for Peyronie's Disease: Results From a Multi-Center Single-Arm Study.
Cocci A; Russo GI; Salonia A; Cito G; Regis F; Polloni G; Giubilei G; Cacciamani G; Capece M; Falcone M; Greco I; Timpano M; Minervini A; Gacci M; Cai T; Garaffa G; Giammusso B; Arcaniolo D; Mirone V; Mondaini N
J Sex Med; 2018 May; 15(5):716-721. PubMed ID: 29699756
[TBL] [Abstract][Full Text] [Related]
3. Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie's Disease: A Matched-Pair Comparison Analysis.
Cocci A; Cito G; Urzì D; Minervini A; Di Maida F; Sessa F; Mari A; Campi R; Falcone M; Capece M; Morelli G; Cacciamani G; Rizzo M; Polito C; Giammusso B; Morgia G; Verze P; Salonia A; Cai T; Mirone V; Mondaini N; Russo GI
J Sex Med; 2018 Oct; 15(10):1472-1477. PubMed ID: 30245025
[TBL] [Abstract][Full Text] [Related]
4. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study.
Levine LA; Cuzin B; Mark S; Gelbard MK; Jones NA; Liu G; Kaufman GJ; Tursi JP; Ralph DJ
J Sex Med; 2015 Jan; 12(1):248-58. PubMed ID: 25388099
[TBL] [Abstract][Full Text] [Related]
5. Collagenase Clostridium histolyticum in the Treatment of Peyronie's Disease-A Review of the Literature and a New Modified Protocol.
Abdel Raheem A; Johnson M; Abdel-Raheem T; Capece M; Ralph D
Sex Med Rev; 2017 Oct; 5(4):529-535. PubMed ID: 28874327
[TBL] [Abstract][Full Text] [Related]
6. Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie's disease.
Gelbard M; Hellstrom WJ; McMahon CG; Levine LA; Smith T; Tursi J; Kaufman G; Goldstein I
J Sex Med; 2013 Nov; 10(11):2822-31. PubMed ID: 24112401
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Curvature Improvement in Men With Peyronie's Disease Treated With Intralesional Collagenase Clostridium Histolyticum.
Flores JM; Nascimento B; Punjani N; Salter CA; Bernie HL; Taniguchi H; Miranda E; Terrier JE; Schofield E; Jenkins L; Mulhall JP
J Sex Med; 2022 Nov; 19(11):1680-1686. PubMed ID: 36127227
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Peyronie's Disease With Collagenase Clostridium histolyticum and Vacuum Therapy: A Randomized, Open-Label Pilot Study.
Ralph DJ; Abdel Raheem A; Liu G
J Sex Med; 2017 Nov; 14(11):1430-1437. PubMed ID: 28974406
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol.
Abdel Raheem A; Capece M; Kalejaiye O; Abdel-Raheem T; Falcone M; Johnson M; Ralph OG; Garaffa G; Christopher AN; Ralph DJ
BJU Int; 2017 Nov; 120(5):717-723. PubMed ID: 28612401
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies.
Gelbard M; Goldstein I; Hellstrom WJ; McMahon CG; Smith T; Tursi J; Jones N; Kaufman GJ; Carson CC
J Urol; 2013 Jul; 190(1):199-207. PubMed ID: 23376148
[TBL] [Abstract][Full Text] [Related]
11. Bother and distress associated with Peyronie's disease: validation of the Peyronie's disease questionnaire.
Hellstrom WJ; Feldman R; Rosen RC; Smith T; Kaufman G; Tursi J
J Urol; 2013 Aug; 190(2):627-34. PubMed ID: 23376705
[TBL] [Abstract][Full Text] [Related]
12. Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional Analysis.
Hellstrom WJG; Tue Nguyen HM; Alzweri L; Chung A; Virasoro R; Tapscott A; Ziegelmann M; Trost L; Gelbard M
J Urol; 2019 Apr; 201(4):777-782. PubMed ID: 30672843
[TBL] [Abstract][Full Text] [Related]
13. Surgical correction of persistent Peyronie's disease following collagenase clostridium histolyticum treatment.
Levine LA; Larsen SM
J Sex Med; 2015 Jan; 12(1):259-64. PubMed ID: 25345351
[TBL] [Abstract][Full Text] [Related]
14. Collagenase Clostridium Histolyticum: A Review in Peyronie's Disease.
Dhillon S
Drugs; 2015 Aug; 75(12):1405-12. PubMed ID: 26201462
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of Men With Peyronie's Disease and Collagenase Clostridium Histolyticum Treatment Failure: Predictors of Surgical Intervention and Outcomes.
Bajic P; Wiggins AB; Ziegelmann MJ; Levine LA
J Sex Med; 2020 May; 17(5):1005-1011. PubMed ID: 32127330
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Safety and Curvature Deformity Characterization in Patients Previously Treated with Collagenase clostridium Histolyticum for Peyronie's Disease.
Goldstein I; Lipshultz LI; McLane M; Hu Y; Xiang Q; Liu G; Vijayan S; Gelbard MK
J Urol; 2020 Jun; 203(6):1191-1197. PubMed ID: 31922462
[TBL] [Abstract][Full Text] [Related]
17. Restoration of Penile Function and Patient Satisfaction with Intralesional Collagenase Clostridium Histolyticum Injection for Peyronie's Disease.
Ziegelmann MJ; Viers BR; McAlvany KL; Bailey GC; Savage JB; Trost LW
J Urol; 2016 Apr; 195(4 Pt 1):1051-6. PubMed ID: 26476353
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Collagenase
Green B; Flores A; Warner J; Kohler T; Helo S; Trost L
J Urol; 2023 Nov; 210(5):791-802. PubMed ID: 37811752
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies.
Lipshultz LI; Goldstein I; Seftel AD; Kaufman GJ; Smith TM; Tursi JP; Burnett AL
BJU Int; 2015 Oct; 116(4):650-6. PubMed ID: 25711400
[TBL] [Abstract][Full Text] [Related]
20. Peyronie's disease response to intralesional collagenase clostridium histolyticum therapy is independent of baseline testosterone.
Schneider D; O'Leary M; Amini E; Miller J; Hassas N; Nguyen J; Hammad MAM; Barham D; Yafi FA
Andrology; 2024 May; 12(4):830-834. PubMed ID: 37753943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
